Vertex Pharmaceuticals (VRTX) Current Assets (2009 - 2026)
Vertex Pharmaceuticals' quarterly Current Assets came in at $11.7 billion in Q1 2026, up 17.2% year-on-year from $10.0 billion in Q1 2025, and up 4.73% quarter-over-quarter from $11.2 billion in Q4 2025.
Vertex Pharmaceuticals has reported Current Assets for 18 years, with the latest figure at $11.7 billion in Q1 2026.
- For the quarter ending Q1 2026, Current Assets rose 17.2% year-over-year to $11.7 billion; the trailing twelve-month figure through Mar 2026 stood at $11.7 billion (up 17.2% YoY), and the FY2025 full-year result was $11.2 billion, up 16.72% from the prior year.
- Current Assets for Q1 2026 stood at $11.7 billion, up from $11.2 billion in the prior quarter.
- The five-year high for Current Assets was $14.7 billion in Q3 2023, with the low at $8.9 billion in Q2 2024.
- Average Current Assets over 5 years is $11.7 billion, with a median of $11.5 billion recorded in 2022.
- Year-over-year, Current Assets surged 38.62% in 2022 and plunged 35.55% in 2024.
- Tracing VRTX's Current Assets over 5 years: stood at $13.2 billion in 2022, then increased by 6.87% to $14.1 billion in 2023, then slumped by 32.15% to $9.6 billion in 2024, then advanced by 16.72% to $11.2 billion in 2025, then advanced by 4.73% to $11.7 billion in 2026.
- The last three Current Assets figures came in at $11.7 billion (Q1 2026), $11.2 billion (Q4 2025), and $10.6 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 10.37 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | 37.31 Mn |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 1.25 Bn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | 73.04 Mn |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 3.59 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 11.73 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 18.21 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 4.22 Bn |
| 10 | Revolution Medicines | 31.20 Bn | 31.20 Bn | - | 1.97 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 11.73 Bn |
| Dec 31, 2025 | 11.20 Bn |
| Sep 30, 2025 | 10.57 Bn |
| Jun 30, 2025 | 10.43 Bn |
| Mar 31, 2025 | 10.01 Bn |
| Dec 31, 2024 | 9.60 Bn |
| Sep 30, 2024 | 9.80 Bn |
| Jun 30, 2024 | 8.94 Bn |
| Mar 31, 2024 | 13.29 Bn |
| Dec 31, 2023 | 14.14 Bn |
| Sep 30, 2023 | 14.70 Bn |
| Jun 30, 2023 | 13.87 Bn |
| Mar 31, 2023 | 12.97 Bn |
| Dec 31, 2022 | 13.23 Bn |
| Sep 30, 2022 | 12.27 Bn |
| Jun 30, 2022 | 11.50 Bn |
| Mar 31, 2022 | 10.36 Bn |
| Dec 31, 2021 | 9.56 Bn |
| Sep 30, 2021 | 8.85 Bn |
| Jun 30, 2021 | 8.46 Bn |
| Mar 31, 2021 | 8.54 Bn |
| Dec 31, 2020 | 8.13 Bn |
| Sep 30, 2020 | 7.46 Bn |
| Jun 30, 2020 | 6.69 Bn |
| Mar 31, 2020 | 5.45 Bn |
| Dec 31, 2019 | 4.82 Bn |
| Sep 30, 2019 | 4.78 Bn |
| Jun 30, 2019 | 4.71 Bn |
| Mar 31, 2019 | 4.18 Bn |
| Dec 31, 2018 | 3.84 Bn |
| Sep 30, 2018 | 3.69 Bn |
| Jun 30, 2018 | 3.41 Bn |
| Mar 31, 2018 | 3.04 Bn |
| Dec 31, 2017 | 2.65 Bn |
| Sep 30, 2017 | 2.33 Bn |
| Jun 30, 2017 | 2.18 Bn |
| Mar 31, 2017 | 1.87 Bn |
| Dec 31, 2016 | 1.83 Bn |
| Sep 30, 2016 | 1.50 Bn |
| Jun 30, 2016 | 1.45 Bn |
| Mar 31, 2016 | 1.40 Bn |
| Dec 31, 2015 | 1.41 Bn |
| Sep 30, 2015 | 1.36 Bn |
| Jun 30, 2015 | 1.29 Bn |
| Mar 31, 2015 | 1.36 Bn |
| Dec 31, 2014 | 1.55 Bn |
| Sep 30, 2014 | 1.65 Bn |
| Jun 30, 2014 | 1.35 Bn |
| Mar 31, 2014 | 1.43 Bn |
| Dec 31, 2013 | 1.59 Bn |
| Sep 30, 2013 | 1.65 Bn |
| Jun 30, 2013 | 1.72 Bn |
| Mar 31, 2013 | 1.57 Bn |
| Dec 31, 2012 | 1.59 Bn |
| Sep 30, 2012 | 1.63 Bn |
| Jun 30, 2012 | 1.59 Bn |
| Mar 31, 2012 | 1.44 Bn |
| Dec 31, 2011 | 1.33 Bn |
| Sep 30, 2011 | 1.25 Bn |
| Mar 31, 2011 | 872.97 Mn |
| Dec 31, 2010 | 1.06 Bn |
| Sep 30, 2010 | 1.23 Bn |
| Jun 30, 2010 | 1.00 Bn |
| Mar 31, 2010 | 1.13 Bn |
| Dec 31, 2009 | 1.31 Bn |